Clinical research of epalrestat tablet in combination with alprostadil injection in the treatment diabetic retinopathy
10.13699/j.cnki.1001-6821.2018.08.006
- VernacularTitle:依帕司他片联合前列地尔注射剂治疗糖尿病视网膜病变的临床研究
- Author:
Wei XIAO
1
;
Ya-Juan MA
;
Lin-Xiu CHEN
;
Jian-Bo GAO
Author Information
1. 浙江省荣军医院眼科
- Keywords:
epalrestat tablet;
alprostadil injection;
diabetic retinopathy;
superoxide dismutase;
total antioxidant capacity;
tumor necrosis factor-α
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(8):934-937
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety profile of epalrestat tablet in combination with alprostadil injection in the treatment of diabetic retinopathy.Methods A total of 92 patients with diabetic retinopathy were randomly divided into the treatment group (n =46) and the control group (n =46).The control group was treated with intravenous drip of alprostadil injection at dose of 5 μg,once daily.The treatment group received oral administration of epalrestat at dose of 50 mg,three times daily.Both groups were treated for 14 d.Clinical efficacy,superoxide dismutase (SOD),total antioxidant capacity (TAOC),tumor necrosis factor-α (TNF-α),blood glucose indicators,and adverse drug reactions between two group was compared between the two groups.Results The total effective rates of the treatment group and control group were 95.65％ (44 cases/46 cases) and 78.26％ (36 cases/46 cases),respectively,and the difference was statistically significant (P ＜0.05).There were significant differences between the treatment group and the control group in the levels of SOD [(88.59 ± 11.02) vs (80.83 ± 10.68)IU · mL-1],TAOC [(20.44±2.25) vs (15.41 ±2.01)IU · mL-1],TNF-α [(11.72±1.55) vs (17.35 ±1.87) ng· L-1],fasting blood glucose [(5.05 ± 0.71) vs (5.92 ± 0.65) mmol · L-1],postprandial blood glucose [(8.20 ± 0.76),(8.80 ± 1.15)mmol · L-1],glycated hemoglobin [(6.17 ±0.85)％ vs (6.77 ±0.82)％] (P ＜0.05).There were no adverse drug reactions in the two groups.Conclusion epalrestat in combination with alprostadil was effective and safe in treating diabetic retinopathy.
